文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

药物遗传学与药效学关联的分析方法

Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics.
PubMed 文献 · Clin Pharmacol Ther · 2021-06-28

本文综述了药物遗传学(PGx)与药效学(PD)关联发现与验证的挑战,重点在于区分药物代谢动力学(PK)变异的影响。以μ阿片受体(OPRM1)遗传变异与阿片反应为例,讨论了因CYP2D6基因型影响部分阿片药物生物活化而难以确认OPRM1效应的原因,并提出未来PGx-PD分析的可能方法及临床转化前景。

要点

  • PGx-PD关联发现较少,部分因PK变异混杂临床结局评估。
  • OPRM1变异与阿片反应关联受CYP2D6基因型影响生物活化干扰。
  • 需采用分析方法区分PK与PD变异,以验证PGx-PD关联。

核心结论

  • PGx-PD关联发现与验证需考虑PK变异的混杂效应,未来分析应整合方法以区分PK与PD贡献。

研究设计与样本

  • 本文为迷你综述,描述近期发现和验证PGx-PD关联的努力,并提出未来分析方法和临床转化讨论。

主要发现

  • 多数PGx研究集中于PK,PGx-PD关联识别较少,部分因PK变异混杂临床结局评估。
  • OPRM1遗传变异对阿片反应的影响因CYP2D6基因型参与可待因和曲马多生物活化而难以确认。

临床怎么用

  • 临床转化PGx-PD需在分析中控制PK变异,以优化治疗结局。

局限性

  • 对相关基因及遗传变异后果理解有限,且PK变异混杂影响PGx-PD关联评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmacogenetics (PGx) seeks to enable selection of the right dose of the right drug for each patient to optimize therapeutic outcomes. Most PGx focuses on pharmacokinetics (PKs), due to our relatively advanced understanding of the genes involved in PKs and the causative effects of variants in those genes. Genetic variants can also affect pharmacodynamics (PDs), but relatively few PGx-PD associations have been identified. This is partially due to a more limited understanding of the relevant genes and the consequences of genetic variation, but is also due in part to the potential confounding of PK variability in assessments of clinical outcomes that have a contribution from both PKs and PDs. For example, it is challenging to confirm the effect of mu opioid receptor (OPRM1) genetic variation on opioid response due to the contribution of CYP2D6 genotype to bioactivation of some opioid drugs (i.e., codeine and tramadol). The objectives of this mini-review are to describe several recent efforts to discover and validate PGx-PD that disentangle the influence of PK variability and propose potential approaches that could be used in future PGx-PD analyses. We use the effect of OPRM1 genetics on opioid response to illustrate how these analyses could be conducted and conclude by discussing how PGx-PD could be translated into clinical practice to improve therapeutic outcomes.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hertz DL, Ramsey LB, Gopalakrishnan M, et al. Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics. Clin Pharmacol Ther. 2021. PMID: 34043820. doi:10.1002/cpt.2312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。